LIXTE’s LB-100 yields 45% greater tumor reduction, IND filing set for H2 2026
LIXTE Biotech’s LB-100, a PP2A inhibitor, enhanced chemotherapy and radiotherapy efficacy in preclinical models, showing up to 45% greater tumor reduction. The company targets an IND filing in H2 2026 to launch Phase 1b/2 trials in ovarian and lung cancer combinations.
1. Preclinical Efficacy Data
In murine ovarian carcinoma models, combining LB-100 with cisplatin and radiation produced up to 45% greater tumor volume reduction compared with standard therapy alone, demonstrating significant synergy in anti-tumor activity.
2. Mechanism of Action
LB-100 functions as a selective protein phosphatase 2A inhibitor, disrupting DNA repair pathways and enhancing apoptosis in cancer cells when used alongside chemotherapy and radiotherapy.
3. Regulatory and Development Timeline
LIXTE plans to submit an investigational new drug application for LB-100 in the second half of 2026, with the goal of initiating Phase 1b/2 combination trials by early 2027.
4. Targeted Indications and Strategy
The upcoming Phase 1b/2 trials will assess safety, tolerability and preliminary efficacy of LB-100 added to standard regimens in ovarian and non-small cell lung cancer patient cohorts.